Actively Recruiting
Dose Escalation and Expansion Study of MCLA-158 Alone or in Combination for Advanced Solid Tumors
Led by Genmab · Updated on 2026-11-02
560
Participants Needed
54
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MCLA-158, a bispecific antibody targeting EGFR and LGR5, in patients with advanced or metastatic solid tumors, including metastatic colorectal cancer mCRC and head and neck squamous cell carcinoma HNSCC. This Phase 12 open-label, multi-center study aims to find the recommended dose for further testing and assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of MCLA-158 alone or combined with other treatments. The study has two parts an initial dose escalation phase that determined the recommended Phase II dose RP2D of MCLA-158, and an expansion phase where this dose is given every two weeks by intravenous infusion to patients with selected solid tumors. The expansion includes single-agent cohorts and combination cohorts where MCLA-158 is tested with pembrolizumab, FOLFIRI chemotherapy, or FOLFOX chemotherapy. Different doses and a subcutaneous formulation are also evaluated in some groups. Participants receive treatment cycles lasting 28 days with infusions on Day 1 and Day 15. Researchers monitor safety through adverse events and dose-limiting toxicities, tumor response, drug levels in blood, and other clinical and laboratory assessments over months to years. The study includes regular evaluations with imaging, laboratory tests, and heart function monitoring, with follow-up extending up to three years to assess response duration, progression-free survival, and overall survival.
CONDITIONS
Brief Title
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here